Tuberculosis
Tackling TB with Science, Strategy, and Scale
At The Aurum Institute, we are a globally recognised leader in tuberculosis (TB) innovation—shaping policy, improving care, and advancing scientific discovery to end TB for good. With operations spanning over 20 high-burden countries, our TB programme combines cutting-edge research, evidence-based implementation, and community-driven solutions.
Our Impact at a Glance
- 2 million+ individuals screened for TB through more than 10 projects
- 210,000 new TB cases identified and treated
- 13.2 million patient courses of 3HP procured across 104 countries
- 140 countries now have access to 3HP through the Aurum-led IMPAACT4TB consortium
- 635,000 people living with HIV and TB contacts reached with preventive care
Programmatic Leadership & Innovation
Aurum's TB portfolio bridges discovery and delivery. From clinical trials and operational research to health systems strengthening, we address TB across the care cascade:
Preventive Therapy & Market Access:
- Leading IMPAACT4TB, a global initiative to scale short-course TB prevention (3HP)
- Driving OPT4TPT to improve uptake and delivery of TB preventive treatment in Africa
Treatment Innovation & Clinical Trials:
- Coordinating panTB-HM, a Phase 2c trial for a universal 4-month regimen against both drug-sensitive and drug-resistant TB
- Co-leading DRTB-HDT, exploring host-directed therapies for rifampicin-resistant TB
Community-Based Models & Policy Influence:
- Pioneering CUT-TB to redefine contact tracing models
- Supporting South Africa’s Global Fund TB Programme in high-burden districts
- Advising national strategies through the TB Think Tank, a policy forum chaired by the National Department of Health
Integrated Response & Collaboration:
- Leading ACCELERATE 1 alongside mothers2mothers to fast-track prevention, early detection, and care
- Generating evidence through multi-country collaborations in Mozambique, Tanzania, Lesotho, Ghana, Ethiopia, and beyond
The Aurum Institute, in collaboration with community partner mothers2mothers, will assist South Africa in accelerating efforts to end TB by prioritising prevention, early detection, appropriate treatment, and retention in care.
Aurum also leads global research trials such as the WHIP3TB trial - a randomized trial evaluating the use of the 3HP regimen for PLHIV given annually - which is funded by the Challenge TB mechanism.
The Global Fund programme, implemented by The Aurum Institute as a Sub-Recipient (SR) of the Global TB Grant (April 2022–March 2025), targets South Africa’s high TB burden. It focuses on 12 districts that account for over 50% of the nation's missing TB cases.
Aurum co-leads and is the African coordinating partner for the TB-Sequel project, a pan-African project to understand the clinical, microbiologic, and host immune factors affecting or predicting the long-term sequelae and socio-economic impact of pulmonary tuberculosis and treatment outcome, taking place in Tanzania, The Gambia, Mozambique and South Africa.
CUT-TB (Community and Universal Testing for TB among contacts) is a 4-year EDCTP funded cluster-randomised pragmatic that is being conduct in South Africa, Tanzania and Lesotho. The study aims to measure effectiveness of universal testing compared to standard TB screening for detection of TB among household and community contacts.
The Opt4TPT (Optimising the delivery cascade for tuberculosis preventive treatment among people living with HIV) study is a three-year programmatic assessment of TPT delivery across three countries, namely Ethiopia, South Africa and Zimbabwe, to generate critical knowledge to improve TPT uptake, implementation and outcomes
DRTB-HDT The EU-funded DRTB-HDT (Stratified Host-Directed Therapy for Drug Resistant Tuberculosis) project will determine if two adjunctive host-directed therapies can prevent the poor outcomes of treatment in cases of RIF-R TB. Patients with RIF-R TB and other risk factors for poor outcome will participate in a randomised, controlled, three-armed multicentre trial.
Latest Highlights
Read the latest news about our impact on TB
No item found!